Clovis Oncology (CLVS) Downgraded to Sell at ValuEngine
ValuEngine cut shares of Clovis Oncology (NASDAQ:CLVS) from a hold rating to a sell rating in a research report released on Tuesday.
CLVS has been the subject of several other research reports. Zacks Investment Research upgraded shares of Clovis Oncology from a hold rating to a buy rating and set a $95.00 target price for the company in a research note on Tuesday, October 17th. Cann reiterated a hold rating on shares of Clovis Oncology in a research note on Monday, September 11th. Oppenheimer reiterated a hold rating on shares of Clovis Oncology in a research note on Tuesday, October 10th. Leerink Swann reiterated an outperform rating and issued a $90.00 target price (down previously from $107.00) on shares of Clovis Oncology in a research note on Wednesday, November 15th. Finally, Barclays initiated coverage on shares of Clovis Oncology in a research note on Monday, October 23rd. They issued an overweight rating and a $105.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $86.15.
Clovis Oncology (CLVS) traded down $1.62 during midday trading on Tuesday, reaching $57.69. 1,170,100 shares of the company were exchanged, compared to its average volume of 1,826,286. Clovis Oncology has a 1-year low of $35.38 and a 1-year high of $99.45. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16.
In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $84.54, for a total transaction of $253,620.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have sold 9,000 shares of company stock valued at $653,220. 12.50% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of CLVS. Neuberger Berman Group LLC bought a new stake in Clovis Oncology during the third quarter valued at approximately $906,000. California Public Employees Retirement System lifted its position in Clovis Oncology by 11.7% during the third quarter. California Public Employees Retirement System now owns 33,384 shares of the biopharmaceutical company’s stock valued at $2,751,000 after purchasing an additional 3,484 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Clovis Oncology during the third quarter valued at approximately $638,000. Bamco Inc. NY lifted its position in Clovis Oncology by 94.1% during the third quarter. Bamco Inc. NY now owns 29,147 shares of the biopharmaceutical company’s stock valued at $2,402,000 after purchasing an additional 14,132 shares during the last quarter. Finally, Crestline Management LP bought a new stake in Clovis Oncology during the third quarter valued at approximately $1,319,000.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.